Mumbai-based BDR Pharmaceutical has launched the first generic Apalutamide (brand name Apatide) in India to treat both metastatic castration sensitive prostrate cancer as well as non-metastatic castration resistant prostrate cancer.

The product will be available across India and shall be of 60 mg strength and available in two packs – 60 tabs and 120 tabs. Apalutamide in combination with anti-androgen therapy will significantly improve chances for survival within metastatic castration sensitive prostrate cancer patients.

Apalutamide plus ADT (androgen-deprivation therapy) arm shows a significant decrease in the risk of disease progression and reduces risk of mortality by 35% amongst non-metastatic castration resistant prostrate cancer. 

Worldwide, prostate cancer burden is expected to grow to 1.7 million new cases and 4, 99,000 new deaths by 2030 simply due to the growth and ageing of the global population. And in India, prostate cancer is the second most common cause of cancer and the sixth leading cause of cancer deaths among men, world over. 

Raheel Shah, Director Business Development, BDR Group stated that “Early identification of newer molecules for life-threatening diseases encourages us to advance the development & introduction of products through the strength of backward integration of developing & manufacturing APIs to facilitate humankind. This type of advanced molecule in the treatment of various cancer indications, is testimony towards our commitment in providing access to affordable medicines without compromising patients’ safety as well as qualitative standards."